relapses

Treatment with Enspryng (satralizumab) for more than two years was shown to prevent relapses in most people with neuromyelitis optica spectrum disorder (NMOSD) in Japan. That’s according to a new study that tracked outcomes from Japanese NMOSD patients given the approved injection therapy in real-world practice. “Overall, most…

Enspryng (satralizumab) is superior to conventional immunosuppressive therapies in reducing the risk of relapses in people with neuromyelitis optica spectrum disorder (NMOSD) for up to three years, and with a comparable safety profile, according to a real-world study. Similar results were obtained when analyzing data only from NMOSD…

The activity of an immune-regulating protein is significantly lower just before or during a relapse in people with neuromyelitis optica spectrum disorder (NMOSD), a recent study has found. This discovery could lead to new ways to monitor disease activity and develop treatments. The protein, called the aryl hydrocarbon receptor…

Treatment with Enspryng (satralizumab) allows nearly all neuromyelitis optica spectrum disorder (NMOSD) patients to remain free of relapses after six months, with many reducing their use of corticosteroids and other immunosuppressants. Nearly one-third of patients were able to stop corticosteroids, which can cause serious side effects when used…

Regular maintenance treatment with low-dose rituximab is associated with less disability and fewer relapses among people with neuromyelitis optica spectrum disorder (NMOSD) compared with receiving irregular doses of the preventive therapy, according to a two-year real-world study in China. “Regular [rituximab] treatment can significantly reduce the annual relapse rate, incidence…

People with neuromyelitis optica spectrum disorder (NMOSD) who test positive for self-reactive antibodies against the aquaporin 4 (AQP4) protein are more likely to be women, and have an earlier disease onset and more relapses than those who test negative. That’s according a single-center study in Argentina that also showed…

A predictive model based on laboratory and clinical risk factors for relapses in neuromyelitis optica spectrum disorder (NMOSD) was found to accurately discriminate NMOSD patients experiencing a relapse within one year of diagnosis from those without a relapse, a study showed. The identified risk factors were numbers and ratios…

Biologic immunosuppressants are more effective than conventional immunosuppressants for people with neuromyelitis optica spectrum disorder (NMSOD) with self-reactive antibodies against the AQP4 protein. That’s according to real-world data from a Japanese study comparing biologic therapies — Soliris (eculizumab), Enspryng (satralizumab), Ultomiris (ravulizumab), Uplizna (inebilizumab), and…

Early use of immunosuppressive therapy — when compared with a later treatment start — was associated with fewer relapses and reduced disability among neuromyelitis optica spectrum disorder (NMOSD) patients with self-reactive antibodies against the AQP4 protein, a study from China showed. The data demonstrated a time-dependent treatment efficacy, with…

The composition of bacteria in the gut is altered in neuromyelitis optica spectrum disorder (NMOSD) patients experiencing disease relapses compared with healthy people in the same household, a study reports. Following treatment, however, the gut bacterial profiles of NMOSD patients in remission resembled those of healthy people. “The…